• Kelun-Biotech received China CDE clearance for its IND for SKB118 (CR-001), a PD-1 x VEGF bispecific antibody, to start trials in advanced solid tumors.
• Crescent Biopharma granted Kelun-Biotech Greater China rights for SKB118 under a December 2025 collaboration.
• Crescent separately disclosed U.S. FDA IND clearance in January 2026 for a global Phase I/II study expected to enroll up to 290 patients.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605122000PR_NEWS_USPR_____CN57208) on May 13, 2026, and is solely responsible for the information contained therein.